13

Kontafarma China Holdings LtdHKG 1312 Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.022

Micro

Exchange

XHKG - Hong Kong Exchange

1312.HK Stock Analysis

13

Uncovered

Kontafarma China Holdings Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-3/100

Low score

Market cap $B

0.022

Dividend yield

Shares outstanding

5 578.71 B

Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. The company employs 1,365 full-time employees The company went IPO on 2012-01-18. The firm operates its business through two business segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of prescription drugs, including chemical drugs and prescribed traditional Chinese medicines, and laboratory related products. The Fitness Business is segment is engaged in the operation of fitness centers, the provision of consultation services for fitness and health activities, as well as the operation of the franchise business for royalty fee income.

View Section: Eyestock Rating